MDNews - Eastern Pennsylvania/Northwest New Jersey

March/April 2012

Issue link: https://viewer.e-digitaledition.com/i/56098

Contents of this Issue

Navigation

Page 21 of 23

++++++++++++++++++++++++++++++ ++++++++++++++++++++++++++++++ +++++++++ +++++++++ +++++++++ +++++++++ +++++++++ ++++++++++++++++++++++++++++++ ++++++++++++++++++++++++++++++ THAT'SNEWS Macular HPV VACCINE Also Recommended for Boys Degeneration Drug Blindsided by Potential Side Effect AN INCREASE IN PRESSURE in the eye prompted concerns about a drug aimed to treat age-related macular degeneration. Ranibizumab (Lucentis), a U.S. Food and Drug Administration-approved injection designed to treat patients suffering from progressive age-related blindness, was linked to an increase of intraocular pressure (IOP) in patients of Sophie Bakri, M.D., a Mayo Clinic ophthalmologist. Two control groups — one group receiving the Lucentis injection and the other not receiving the injection — were evaluated during a two-year study to determine the drug's effectiveness in treating multiple forms of macular degeneration. The study did reveal an increase in IOP in patients who had received the injection, regardless of pre-existing risk factors, such as ocular hypertension and glaucoma. Dr. Bakri concluded that though it couldn't be determined why the ranibizumab injection increases IOP, her findings suggested that IOP should be closely monitored in those receiving the treatment. ■ GOVERNMENT OFFICIALS CAME to a consensus on recommending the human papillomavirus (HPV) vaccine Gardasil for boys between ages 11 and 21. The vaccine — currently administered to girls and young women — has been approved for males since 2009. Officials debated the cost effectiveness of giving boys the vaccine. The three-dose series, given over a six-month period, costs $120 per dose, and giving the vaccine to boys is estimated to cost $38 million overall. According to the Centers for Disease Control and Prevention, nearly 20 million Americans are infected with HPV, which can lead to cervical and other cancers. The vaccine is designed to help protect both girls and boys from the virus. A study by the Guttmacher Institute revealed that 13% of all 15-year-olds sur- veyed have had vaginal sex, with figures increasing to 70% by age 19. According to the CDC, the HPV vaccine is more effective when given to young teens before sexual activity begins. Controversy has sparked over the vac- cine due to parents' fears that the vaccine could be dangerous, its effectiveness in preventing cervical cancer and whether government officials should require it for school-aged children. ■ ADVERTISERS' INDEX Bennett Infiniti ..........................................17 Cedar Crest Professional Park ..............3 Fitzpatrick Lentz & Bubba ..................22 Jaguar of Allentown .............. Inside Back Cover Keurig .......................... Inside Front Cover Knopf Automotive ...................................19 Moravian Academy ...................................11 Moravian Hall Square ..............................18 Nixon Uniform Service and Medical Wear .........................................3 Phoenicia ....................................................15 Range Rover of Allentown ......... Inside Back Cover RCN Business Services ...........................21 St. Luke's Heart & Vascular Center .................................Back Cover

Articles in this issue

Links on this page

Archives of this issue

view archives of MDNews - Eastern Pennsylvania/Northwest New Jersey - March/April 2012